RARE DISEASES A–Z · LETTER S
Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an inherited condition in which the motor neurons of the spinal cord — the cells that drive the muscles — die because they lack a protein called SMN. It has become the emblem of modern genetic medicine: within a decade it went from untreatable to having three effective therapies.
By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026
Rare Diseases A–Z is part of the MedicalVideos.com education program. It is produced independently of sponsors, and any future sponsorship will be labelled on the hub.
The guide
The basics
Motor neurons need SMN protein to survive; a backup gene (SMN2) makes only a little, and how many copies of it a child inherits largely sets the severity. Type 1 (the commonest severe form) appears before six months: babies are floppy, feed and breathe poorly, and never sit — historically the leading genetic cause of infant death. Type 2 children sit but never walk independently; type 3 children walk but may lose that ability; type 4 is mild and adult-onset. Weakness is symmetrical and worse in the legs and trunk; the mind is unaffected, and children with SMA are typically bright and sociable. Breathing muscles, swallowing, and the spine (scoliosis) are the medical battlegrounds in the severe types.
How it works
Genetic testing for the SMN1 deletion confirms the diagnosis quickly and is now the first test in a floppy infant — no biopsy or EMG needed. SMN2 copy number is reported alongside, as it guides prognosis and treatment urgency. Newborn screening for SMA (from the same heel-prick blood spot as other conditions) is in place in many regions precisely because treatment timing is everything. Assessment covers breathing (including sleep studies), swallowing and nutrition, spine, hips, and contractures. Carrier testing is offered to parents and, later, siblings — carriers are common (roughly 1 in 40 to 1 in 60 people, varying by population), which is why SMA can appear in families with no history.
Day to day
Three disease-modifying treatments have transformed SMA since 2016. An antisense medicine injected into the spinal fluid at intervals makes SMN2 produce more working protein. A one-time intravenous gene therapy delivers a replacement SMN1 gene and is given to infants and young children. A daily oral medicine achieves the same splicing correction as the injection and suits all ages. All work best early — children treated before symptoms often develop near-normally — and all have stabilised or improved outcomes in older patients too. Supportive care remains essential: breathing support (including non-invasive ventilation and cough assist), feeding support, scoliosis surgery when needed, physiotherapy, and mobility equipment. The landscape keeps moving; centre teams track eligibility as approvals widen.
When to get help
Care is coordinated by a neuromuscular centre: neurology, respiratory, dietetics, physiotherapy, occupational therapy, orthopaedics, and palliative care for the most severe presentations. Reviews track breathing and sleep, nutrition and growth, spine curvature, and function. Report chest infections early — weak cough makes them dangerous — and keep vaccinations, including flu and RSV prevention where offered, current. Families of infants with type 1 face difficult decisions even in the treatment era; centres provide honest prognostic conversations and time to decide. Genetic counselling covers the 1-in-4 recurrence risk and options for future pregnancies, including prenatal and embryo testing.
Common questions
What is SMN2, and why does it matter?
Almost everyone has a second, similar gene (SMN2) that makes a small amount of the same protein. The number of SMN2 copies a person has is the main predictor of severity — more copies, milder disease — and two of the three modern treatments work by making SMN2 produce more full-length protein.
Is SMA screened for at birth?
Yes, in many regions — SMA was added to newborn screening panels because treatment before symptoms produces dramatically better outcomes, with many presymptomatically treated children walking on schedule. Where screening exists, a positive result triggers urgent referral and treatment within days to weeks.
How do the three treatments differ?
The three treatments work differently: an oral daily medicine and an injected spinal medicine both modify SMN2 splicing to raise protein production, while gene therapy delivers a new SMN1 copy in a single infusion. Choice depends on age, weight, antibodies to the gene-therapy virus, and family preference, guided by the specialist centre.
Can adults with SMA be treated?
Adults benefit too: the splicing medicines stabilise or modestly improve strength and function in adults with type 2 and 3 SMA, and are licensed for them. Expectations are set honestly — stabilisation is a win against a background of slow decline — and rehabilitation multiplies the benefit.
More in Letter S
Related
Sources
- Spinal Muscular Atrophy (MedlinePlus)
- Spinal Muscular Atrophy — MedlinePlus Genetics (MedlinePlus)
- Spinal Muscular Atrophy (National Organization for Rare Disorders (NORD))
This guide is general information, not medical advice. Rare diseases are individual — diagnosis and treatment depend on your own results, other conditions, and treatment history, and are set by your treating team. Never start, stop, or change a medicine because of something you read here. If you have severe breathlessness, uncontrolled bleeding, confusion, sudden weakness, or thoughts of harming yourself, seek urgent care. Disease-modifying therapy choice and timing are individual; follow your neuromuscular centre's plan.